Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of GSK2983559 in Healthy Participants
NCT03358407Phase 1Terminated
- Sponsor
- GSK
- Start
- Jan 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2983559 in inflammatory bowel disease (IBD) (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) up to 11 weeks, Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI) up to 11 weeks and 9 more. Started Jan 2018; status: terminated.
02
Drugs
GSK2983559
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03358407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358407.